NCT03081494View on ClinicalTrials.gov

Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 9, 2017

Primary Completion Date

May 7, 2019

Study Completion Date

May 7, 2019

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

spartalizumab (PDR001)

100 mg lyophilisate in vial received 400 mg every 4 weeks

DRUG

regorafenib

120 mg once daily first 21 days of each 28-day cycle (=4 weeks)

Trial Locations (11)

2065

Novartis Investigative Site, St Leonards

6150

Novartis Investigative Site, Murdoch

20089

Novartis Investigative Site, Rozzano

20162

Novartis Investigative Site, Milan

28041

Novartis Investigative Site, Madrid

169610

Novartis Investigative Site, Singapore

6423906

Novartis Investigative Site, Tel Aviv

H3T 1E2

Novartis Investigative Site, Montreal

2333 ZA

Novartis Investigative Site, Leiden

05505

Novartis Investigative Site, Seoul

08035

Novartis Investigative Site, Barcelona

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY